[F]-(2S,4R)4-Fluoroglutamine PET Imaging of Glutamine Metabolism in Murine Models of Hepatocellular Carcinoma (HCC)

Overview

Journal Mol Imaging

Publisher Sage Publications

Specialty Radiology

Date 2022 Aug 15

PMID 35967756

Authors

Youngho Seo

Miranda C Craig

Stephanie T Murphy

Jinjin Feng

Xin Chen

Mariia Yuneva

Affiliations

Soon will be listed here.

Abstract

Purpose: Quantitative [F]-(2S,4R)4-fluoroglutamine ([F]4-FGln or more simply [F]FGln) metabolic kinetic parameters are compared with activity levels of glutamine metabolism in different types of hepatocellular carcinoma (HCC).

Methods: For this study, we used two transgenic mouse models of HCC induced by protooncogenes, MYC, and MET. Biochemical data have shown that tumors induced by MYC have increased levels of glutamine metabolism compared to those induced by MET. One-hour dynamic [F]FGln PET data were acquired and reconstructed for fasted MYC mice ( = 11 tumors from 7 animals), fasted MET mice ( = 8 tumors from 6 animals), fasted FVBN controls ( = 8 normal liver regions from 6 animals), nonfasted MYC mice ( = 16 tumors from 6 animals), and nonfasted FVBN controls ( = 8 normal liver regions from 3 animals). The influx rate constants ( ) using the one-tissue compartment model were derived for each tumor with the left ventricular blood pool input function.

Results: Influx rate constants were significantly higher for MYC tumors ( = 0.374 ± 0.133) than for MET tumors ( = 0.141 ± 0.058) under fasting conditions ( = 0.0002). Rate constants were also significantly lower for MET tumors ( = 0.141 ± 0.135) than normal livers ( = 0.332 ± 0.179) under fasting conditions ( = 0.0123). Fasting conditions tested for MYC tumors and normal livers did not result in any significant difference with values > 0.005.

Conclusion: Higher influx rate constants corresponded to elevated levels of glutamine metabolism as determined by biochemical assays. The data showed that there is a distinctive difference in glutamine metabolism between MYC and MET tumors. Our study has demonstrated the potential of [F]FGln PET imaging as a tool to assess glutamine metabolism in HCC tumors with a caution that it may not be able to clearly distinguish HCC tumors from normal liver tissue.

Citing Articles

Radiosynthesis and Analysis of (S)-4-(3-[F]Fluoropropyl)-L-Glutamic Acid.

Brown G, Soloviev D, Lewis D Mol Imaging Biol. 2022; 25(3):586-595.

PMID: 36525163 PMC: 10172245. DOI: 10.1007/s11307-022-01793-3.

References

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Zhou R, Pantel A, Li S, Lieberman B, Ploessl K, Choi H . [F](2,4)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition. Cancer Res. 2017; 77(6):1476-1484. PMC: 5362115. DOI: 10.1158/0008-5472.CAN-16-1945. View

Shyer J, Flavell R, Bailis W . Metabolic signaling in T cells. Cell Res. 2020; 30(8):649-659. PMC: 7395146. DOI: 10.1038/s41422-020-0379-5. View

Li L, Che L, Wang C, Blecha J, Li X, VanBrocklin H . [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol. 2015; 18(3):360-7. PMC: 4866912. DOI: 10.1007/s11307-015-0915-8. View

Ward P, Thompson C . Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308. PMC: 3311998. DOI: 10.1016/j.ccr.2012.02.014. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Ren Z, Chen X, Hong L, Zhao X, Cui G, Li A . Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis. Small. 2019; 16(2):e1905233. DOI: 10.1002/smll.201905233. View

Kim M, Parolia A, Dunphy M, Venneti S . Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat Rev Clin Oncol. 2016; 13(12):725-739. PMC: 5115958. DOI: 10.1038/nrclinonc.2016.108. View

Dunphy M, Harding J, Venneti S, Zhang H, Burnazi E, Bromberg J . In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine. Radiology. 2018; 287(2):667-675. PMC: 5929369. DOI: 10.1148/radiol.2017162610. View

10.

Shachaf C, Kopelman A, Arvanitis C, Karlsson A, Beer S, Mandl S . MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004; 431(7012):1112-7. DOI: 10.1038/nature03043. View

11.

Qu W, Zha Z, Ploessl K, Lieberman B, Zhu L, Wise D . Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors. J Am Chem Soc. 2010; 133(4):1122-33. DOI: 10.1021/ja109203d. View

12.

Wang W, Wei C . Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020; 7(3):308-319. PMC: 7452544. DOI: 10.1016/j.gendis.2020.01.014. View

13.

Giordano S, Columbano A . Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 2013; 60(2):442-52. DOI: 10.1016/j.jhep.2013.09.009. View

14.

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

15.

Wang R, Dillon C, Shi L, Milasta S, Carter R, Finkelstein D . The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011; 35(6):871-82. PMC: 3248798. DOI: 10.1016/j.immuni.2011.09.021. View

16.

Feng M, Xiong G, Cao Z, Yang G, Zheng S, Qiu J . LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J Exp Clin Cancer Res. 2018; 37(1):274. PMC: 6233565. DOI: 10.1186/s13046-018-0947-4. View

17.

Shanware N, Mullen A, DeBerardinis R, Abraham R . Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl). 2011; 89(3):229-36. DOI: 10.1007/s00109-011-0731-9. View

18.

Miner M, Liljenback H, Virta J, Merisaari J, Oikonen V, Westermarck J . (2S, 4R)-4-[F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models. Mol Imaging Biol. 2020; 22(4):969-978. PMC: 7343746. DOI: 10.1007/s11307-020-01472-1. View

19.

Chen X, Wang Z, Zhao X, Zhang L, Zhou L, Li X . STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene. 2022; 41(17):2492-2504. DOI: 10.1038/s41388-022-02273-2. View

20.

Mendez-Lucas A, Lin W, Driscoll P, Legrave N, Novellasdemunt L, Xie C . Identifying strategies to target the metabolic flexibility of tumours. Nat Metab. 2020; 2(4):335-350. PMC: 7436715. DOI: 10.1038/s42255-020-0195-8. View